mRNA 치료제의 세계 시장조사 보고서

Report Highlights

The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.

Summary:

The global market for mRNA therapeutics reached $REDACTED billion in 2022 and is estimated to reach $REDACTED billion by the end of 2028. It is expected to decline at the CAGR of REDACTED% during the forecast period. The decline, which stems from the end of COVID-19 pandemic, should be mitigated by the introduction of new drugs during the forecast period.

The COVID-19 pandemic created a niche market for mRNA therapeutics, particularly vaccines. Developed countries used mRNA vaccines for protection against the severe acute respiratory syndrome (SARS)-CoV-2. The fast-paced development of mRNA vaccines was possible due to advancement in sequencing as well as two decades of previous research on mRNA drugs. mRNA drugs should become a major segment of vaccines and therapeutics.

The mechanism of action of mRNA vaccine is like that elucidated by the protein-based vaccines. The mRNA particle, which is inserted into a healthy patient, carries the code for an antigen (a small piece of protein found on the virus’s outer membrane). Viral proteins are produced via the mRNA code. The body recognizes it as a foreign material and produces antibodies necessary for the protection against the diseases.

Key factors driving the mRNA global market include the increasing number of pandemics and epidemic diseases. In the past 20 years, the world has experienced the two epidemics: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS); and the pandemic COVID-19. These situations highlighted the need for technologies like mRNA that are easy to produce and upscale quickly. The COVID-19 pandemic pushed mRNA therapeutics to the forefront of the pharma and bio-pharma industries.

Another key growth factor is the pharmaceutical industry’s investment in the mRNA segment. Large pharmaceutical companies are seeking innovative drugs that have limited side effects. mRNA presents one such opportunity. Also, private investments are increasing in this segment, driven by the COVID-19 pandemic.

However, the market also is facing a few challenges, such as lack of standard regulations that affect a different class of therapeutics. This leads to confusion for new and existing players for which pathway to follow. Existing and new technologies, such as protein and CRISP, respectively, also pose competition.

The pipeline of mRNA drugs is robust. Under favorable conditions, a drug should enter the market by late 2024 or early 2025. Currently, the majority of drugs in the pipeline target infectious diseases or are being developed as vaccines. Also, therapeutic drugs target cancer treatment. Some drugs have received fast-track status from the FDA, increasing the pace of those clinical trials due to their promising results. Drug trials using mRNA vaccines are showing efficacy in the range of REDACTED% to REDACTED%. There are 2 influenzas vaccines which are, under phase 3 clinical trials and will be commercialized during the forecast period.

Report Scope:

This report focuses on the mRNA therapeutics market. This reports include the types of mRNA and their application in therapy. Also, the report focuses on the patent analysis and clinical trial analysis of mRNA. The report also portrays the trends and dynamics affecting the market during the study period. The study covers market projections through 2028 and profiles major market players.

By geography, the market is segregated into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The market is estimated through 2028.

BCC Research also summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022 and identifies the trends in this activity.

Report Synopsis

Report Includes:

• 37 data tables and 27 additional tables
• An overview of the global market related to mRNA therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
• Coverage of the pandemic threats, therapeutic developments, and new technologies in the market
• Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
• Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
• Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
• Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
• Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
• Profiles of leading market participants

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What’s New in This Update?
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Evolution of RNA Therapeutics
History of RNA Therapeutics
Development of RNA Therapeutics and Types
DNA Therapeutics vs. RNA Therapeutics
Clinical Need for RNA Therapeutics
Increasing Disease Population and Economic Burden
Limitations of Traditional Therapeutics
Therapeutic Limitations of Biologics
Poor Management of Chronic Diseases
Limited Treatment for Rare Diseases
RNA Therapeutics
Antisense Oligonucleotide (ASO) as Therapeutics
Small Interfering RNA (siRNA) as Therapeutics
miRNA as Therapeutics
Aptamers as Therapeutics
mRNA as Therapeutics
Manufacturing RNA-Based Biopharmaceuticals
Chromatographic Purification Steps
Delivery of RNA Therapeutics
Polymer Conjugation/Chemical Modification
Encapsulation
Lipid-Based Nanoparticles
Polymer Nanomaterials
Silica Nanoparticles
Carbon and Gold Nanomaterials
GalNAc
Institution and Hospital-Based RNA Therapeutics
Regulatory Influence on the Market for RNA Therapeutics
Impact of COVID-19
Chapter 4 Market Dynamics
Market Dynamics
Drivers
Restraints
Opportunities
Chapter 5 Target Disease and Disorders
Overview of Common Diseases and Disorders for mRNA Therapeutics
Cancer
Infectious Diseases
Cardiovascular Disease
Lifestyle Disorders
Respiratory Disorders
Musculoskeletal Disorders
Gastrointestinal Disorders
Urology Disorders
Nephrology Disorders
Immune Disorders
Neurological Disorders
Rare Diseases
Other Disorders
Tobacco Smoking and Associated Diseases
Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
Chronic Diseases: Expanding Horizon for mRNA Therapeutics
Unmet Needs of Rare Diseases: mRNA Therapeutics
Aging, Gender and Onset of Diseases
Global Demographics
U.S. Demographics
European Demographics
Japanese Demographics
Chapter 6 Pipeline and Clinical Trial Analysis
mRNA Vaccines
mRNA Therapeutics
Clinical Trial Analysis
Chapter 7 Market Breakdown by Product
Mechanism of Action of mRNA COVID Vaccines
Three Most-Advanced mRNA Vaccines
Chapter 8 Market Breakdown by Region
North America
Canada
Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
RoW
Chapter 9 Emerging Technologies and Developments
Overview
Nanoparticles
Modified mRNA
Automated mRNA Synthesis Kits
Bio Platforms
Chapter 10 Patent Analysis
Patent Analysis
mRNA Publication
Chapter 11 Outlook for Mergers & Acquisitions, and Venture Funding
Chapter 12 Competitive Intelligence
Chapter 13 Company Profiles
ARCTUR U.S. THERAPEUTICS INC.
BIONTECH SE
CUREVAC N.V.
GENNOVA BIOPHARMACEUTICALS LTD.
MERCK KGAA
MODERNA INC.
NUTCRACKER THERAPEUTICS
OMEGA THERAPEUTICS INC.
STRAND THERAPEUTICS
VAXESS TECHNOLOGIES INC.

List of Tables
Summary Table : Global Market for mRNA Therapeutics, by Type, Through 2028
Table 1 : COVID-19: Total Cases and Deaths, by Select Country, 2023
Table 2 : Pandemics of the 21st Century
Table 3 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
Table 4 : Global Epidemiology of Colorectal Cancer Cases, by Region, Through 2030
Table 5 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 6 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Table 7 : Case Fatality Rate, Global Viral Outbreaks, 2020
Table 8 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
Table 9 : Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
Table 10 : Global Prevalence of CHF and Stroke, Through 2030
Table 11 : Structural Heart Disease Management Through Medications
Table 12 : BMI Categories Based on Increasing Health Risks
Table 13 : Trends in Obesity Composition of the Global Population, Through 2025
Table 14 : Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
Table 15 : Global Distribution of Diabetes, by Type
Table 16 : Global Prevalence of Diabetes, by Type, Through 2040
Table 17 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, Through 2025
Table 18 : Global Deaths, by Type of Musculoskeletal Disorder, Through 2030
Table 19 : Global Deaths from Digestive Diseases, by Region, Through 2025
Table 20 : Global Distribution of Mortality, by Chronic Disease Type, 2019
Table 21 : Global Distribution of DALYs, by Chronic Disease Type, 2019
Table 22 : Estimated World Population and Annual Growth, by Age Group, Through 2030
Table 23 : Total Global Population, by Select Country/Region, Through 2030
Table 24 : U.S. Population Projections and Estimates, by Age Group, Through 2030
Table 25 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
Table 26 : European Population Estimates and Projections, by Age Group, Through 2030
Table 27 : Japanese Population Estimates and Projections, by Age Group, Through 2030
Table 28 : Clinical Trials on mRNA Vaccine Candidates, 2023
Table 29 : Clinical Trials on mRNA Vaccine Candidates for Cancer Treatments, as of 2023
Table 30 : Clinical Trials on mRNA Therapeutic Application
Table 31 : Properties of BNT162b2 Vaccine
Table 32 : Properties of mRNA-1273 Vaccine
Table 33 : Properties of CVnCoV Vaccine
Table 34 : Global Market for COVID Vaccines, by Region, Through 2028
Table 35 : Global Market for Non-COVID mRNA Therapeutics, by Region, Through 2028
Table 36 : Global Market for mRNA Therapeutics, by Region, Through 2028
Table 37 : North American Market for mRNA Therapeutics, by Type, Through 2028
Table 38 : European Market for mRNA Therapeutics, by Type, Through 2028
Table 39 : Asia-Pacific Market for mRNA Therapeutics, by Type, Through 2028
Table 40 : RoW Market for mRNA Therapeutics, by Type, Through 2028
Table 41 : mRNA Patents: Top 10 Organizations
Table 42 : Notable Patents for mRNA Therapeutics
Table 43 : Some of the Notable Patents Related to mRNA Vaccines for Infectious Diseases
Table 44 : Some of the Notable Patents Related to mRNA Vaccines for Cancer
Table 45 : Notable Patents Focused on mRNA Delivery and Modification
Table 46 : Recent M&A Deals on mRNA Therapeutics Company, 2006-2021
Table 47 : Major Development of Company Profiles, 2021-2023
Table 48 : BioNTech: Annual Revenue, 2021 and 2022
Table 49 : BioNTech: News, 2021-2023
Table 50 : BioNTech: ESG Developments, 2021
Table 51 : BioNTech: Pipeline Products
Table 52 : CureVac: Annual Revenue, 2021 and 2022
Table 53 : CureVac: News, 2021-2023
Table 54 : CureVac: Pipeline
Table 55 : Merck: Annual Revenue, 2021 and 2022
Table 56 : Merck: miRNA Product Portfolio
Table 57 : Merck: Key Developments, Jan 2021-May 2023
Table 58 : Moderna Inc.: Annual Revenue, 2021 and 2022
Table 59 : Moderna Inc.: News, 2021-2023
Table 60 : Moderna Inc.: Pipeline Products
Table 61 : Nutcracker Therapeutics: Pipeline Products
Table 62 : Strand Therapeutics: Pipeline Products
Table 63 : Strand Therapeutics: News, 2021-2023

List of Figures
Summary Figure : Global Market for mRNA Therapeutics, by Type, 2021-2028
Figure 1 : Development Timeline: COVID-19 mRNA Vaccines
Figure 2 : Reasons for Increasing Pandemics
Figure 3 : Benefits of Vaccination
Figure 4 : Investment in RNA Therapeutics 2011 to 2021
Figure 5 : Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
Figure 6 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
Figure 7 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Figure 8 : Case Fatality Rate Share, Global Viral Outbreaks, 2020
Figure 9 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
Figure 10 : Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
Figure 11 : Global Prevalence of CHF and Stroke, 2004-2030
Figure 12 : Trends in Obesity Composition of the Global Population, 2012-2025
Figure 13 : Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
Figure 14 : Global Distribution of Diabetes, by Type
Figure 15 : Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 16 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, 2012-2025
Figure 17 : Global Deaths, by Type of Musculoskeletal Disorder, 2000-2030
Figure 18 : Global Distribution of Mortality, by Chronic Disease Type, 2019
Figure 19 : Global Distribution of DALYs, by Chronic Disease Type, 2019
Figure 20 : Estimated World Population and Annual Growth, by Age Group, 2000-2030
Figure 21 : Total Global Population, by Select Country/Region, 2000-2030
Figure 22 : U.S. Population Estimates and Projections, by Age Group, 2000-2030
Figure 23 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
Figure 24 : European Population Estimates and Projections, by Age Group, 2000-2030
Figure 25 : Japanese Population Estimates and Projections, by Age Group, 2000-2030
Figure 26 : Distribution of Clinical Trials on mRNA Vaccines, by Disease Indication, 2023
Figure 27 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023
Figure 28 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Mode of Administration, 2023
Figure 29 : Clinical Trials on mRNA Therapeutics, Based on Recruiting Status, January 2020 to October 2023
Figure 30 : Share of Clinical Trials on mRNA Therapeutics, With or Without Results, January 2020 to October 2023
Figure 31 : Clinical Trials on mRNA Therapeutics, Based on Age Group, January 2020 to October 2023
Figure 32 : Share of Clinical Trials on mRNA Therapeutics, Based on Gender, January 2020 to October 2023
Figure 33 : Share of Clinical Trials on mRNA Therapeutics, by Trial Phase, January 2020 to October 2023
Figure 34 : Share of Clinical Trials on mRNA Therapeutics, by Type of Funder, January 2020 to October 2023
Figure 35 : Share of Clinical Trials on mRNA Therapeutics, by Enrollment Number, January 2020 to October 2023
Figure 36 : Share of Clinical Trials on mRNA Therapeutics, by Interventional Mode, January 2020 to October 2023
Figure 37 : Share of Clinical Trials on mRNA Therapeutics, by Type, January 2020 to October 2023
Figure 38 : Global Market for mRNA Therapeutics, 2021-2028
Figure 39 : Innovations in mRNA Therapeutics
Figure 40 : mRNA Based Patent Publications, 2019-2021
Figure 41 : Patents on mRNA Therapeutics, 2010-2021
Figure 42 : Share of Patents on mRNA Therapeutics, by Patent Classification, 2010 to 2021
Figure 43 : Funding in the mRNA Market, by Various Sources, 2021-2023
Figure 44 : Top Three Companies: mRNA Vaccines and Therapeutics
Figure 45 : Share of Key Growth Strategies of Major Companies, 2021-2023
Figure 46 : BioNTech: Annual Revenue, 2021 and 2022
Figure 47 : CureVac: Annual Revenue, 2020 and 2021
Figure 48 : Merck: Annual Revenue, 2021 and 2022
Figure 49 : Merck: Market Share, by Business Segment, 2022
Figure 50 : Merck: Revenue Share, by Region, 2022
Figure 51 : Moderna Inc.: Annual Revenue, 2021 and 2022
Figure 52 : Moderna Inc.: Revenue Share, by Segment, 2022